HRG Group, Inc. (NYSE:HRG) shares fell -4.66% in last trading session and ended the day at $11.45. HRG Gross Margin is 47.70% and its has a return on assets of -1.30%. HRG Group, Inc. (NYSE:HRG) quarterly performance is -11.51%.
HRG Group, Inc., formerly Harbinger Group Inc., is a holding company. The Company’s operations are conducted through Fidelity & Guaranty Life (FGL), that offers life insurance and annuity products; Front Street Re (Delaware) Ltd. (Front Street), which offers reinsurance; Salus Capital Partners, LLC (Salus), Five Island Asset Management, LLC (FIAM), which holds interests in FIAM Capital Management, LLC (Five Island), Energy & Infrastructure Capital (EIC) and CorAmerica Capital, LLC (CorAmerica) offer financing and asset management, Spectrum Brands Holdings, Inc. (Spectrum Brands), which provides consumer products, such as batteries, small appliances.
Physicians Realty Trust (NYSE:DOC) ended the last trading day at $14.96. Company weekly volatility is calculated as 1.66% and price to cash ratio as 47.43. Physicians Realty Trust (NYSE:DOC) showed a weekly performance of -2.67%.
Physicians Realty Trust is a self-managed healthcare real estate company organized to acquire, selectively develop, own and manage healthcare properties that are leased to physicians, hospitals and healthcare delivery systems. The Company invests in real estate that is integral to providing high quality healthcare. The Company is a Maryland real estate investment trust and elected to be taxed as a REIT for U.S. federal income tax purposes beginning with its short taxable year ended December 31, 2013.
Physicians Realty Trust (NYSE:DOC) announced that the Company’s Board of Trustees has authorized and the Company has declared a quarterly cash dividend of $0.225 per common share for the quarter ending September 30, 2015. The dividend will be payable on October 30, 2015, to common shareholders and unit holders of record on October 16, 2015.
On 28 September, Buffalo Wild Wings Inc. (NASDAQ:BWLD) shares fell -1.81% and was closed at $193.19. BWLD EPS growth in last 5 year was 24.00%. Buffalo Wild Wings Inc. (NASDAQ:BWLD) year to date (YTD) performance is 7.10%.
Credit Suisse reaffirmed their sell rating on shares of Buffalo Wild Wings (NASDAQ:BWLD) in a research report sent to investors on Tuesday, AnalystRatings.Net reports.
Buffalo Wild Wings, Inc. is an owner, operator, and franchisor of restaurants featuring a variety of menu items, including its Buffalo, New York-style chicken wings. The Company operates Buffalo Wild Wings and Emerging brands (PizzaRev and Rusty Taco) restaurants, as well as selling Buffalo Wild Wings and Rusty Taco restaurant franchises. It offers a variety of sauces and seasonings, which include Sweet BBQ, Teriyaki, Mild, Medium, Honey BBQ, Spicy Garlic, Buffalo, Desert Heat, Chipotle BBQ, Lemon Pepper and Salt & Vinegar, among others. Its menu includes a variety of food items, including Sharables, Wild Flatbreads, specialty hamburgers and sandwiches, wraps, Buffalito soft tacos and salads.
Can-Fite BioPharma Ltd. (NYSEMKT:CANF) shares fell -19.79% in last trading session and ended the day at $3.81. Can-Fite BioPharma Ltd. (NYSEMKT:CANF) quarterly performance is 71.62%.
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team.
On 24 September, Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (announced that it has closed its previously announced registered direct offering with institutional investors for gross proceeds of $9 million.
Sangamo Biosciences Inc. (NASDAQ:SGMO) caters to the Healthcare space. It has a net profit margin of -59.30% and weekly performance is -12.61%. On the last day of trading company shares ended up at $6.17. Sangamo Biosciences Inc. (NASDAQ:SGMO) distance from 50-day simple moving average (SMA50) is -22.76%.
Sangamo BioSciences, Inc. is focused on Engineering Genetic CuresTM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728).
Sangamo BioSciences, Inc. (NASDAQ:SGMO) presented data demonstrating sustained functional control of viral load in the absence of antiretroviral drugs (ART) in two of three HIV-infected subjects treated in Cohort 3* of its Phase 1/2 study (SB-728-1101) of its ZFP Therapeutic (SB-728-T) for the treatment of HIV/AIDS. The subjects remain on extended treatment interruption (TI), past the initial 16 week TI period. The data, which led to expanded enrollment of this Cohort, were presented at the 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego from September 17-21.
Leave a Reply